MYCi975 is a small molecule inhibitor, which binds MYC directly to disrupt MYC-MAX interaction and increases the proteasomal degradation of MYC, and thus leads to decreased tumor growth (Han et al., 2019; Truica et al., 2021). Here, MYC is linked to neoplasm.